Asia Pacific Ophthalmic Drugs Market Size & Outlook
- Pharmaceuticals
- Ophthalmology Drugs
- Ophthalmic Drugs Market Outlook
- Ophthalmology Drugs
Global Market
Related Markets
Ask a question about the ophthalmic drugs market
Asia Pacific ophthalmic drugs market highlights
- The Asia Pacific ophthalmic drugs market generated a revenue of USD 7,587.0 million in 2025.
- The market is expected to grow at a CAGR of 10.1% from 2026 to 2033.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2025.
- Gene & Cell Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 7,587.0 million |
| Market revenue in 2033 | USD 16,421.5 million |
| Growth rate | 10.1% (CAGR from 2026 to 2033) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Gene & Cell Therapy |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-VEGF agents, Anti-glaucoma, Anti-inflammatory, Anti-Allergy, Gene & Cell Therapy |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.3% of the global ophthalmic drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 16,421.5 million by 2033.
Asia Pacific is expected to grow at the fastest rate of 10.0% over the forecast period. The increasing burden of ophthalmic disorders and rising consumer awareness are expected to drive market growth in Asia Pacific. Nearly two-thirds of the Asia Pacific population is vision impaired or blind.
The presence of a welldistributed network of clinical laboratories and hospitals in India is enabling an improved market penetration of ophthalmic drugs. In addition, rapid economic development and an increase in awareness programs in this region are anticipated to propel market growth.
Asia Pacific consists of a blend of developing and developed economies. Increasing healthcare expenditure in the region is anticipated to fuel market growth. The increasing geriatric population and rising awareness of dry eye syndrome are among the major factors driving the market in this region.
No credit card required*
Publish Date: Apr 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Alcon Inc | View profile | 25,315 | Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 | www.alcon.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Bausch Health Companies Inc | View profile | 20,270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | www.bauschhealth.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | gene.com |
| Coherus BioSciences Inc | View profile | 306 | 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 | www.coherus.com |
Asia Pacific Ophthalmic Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Ophthalmic Drugs Market Outlook will help companies and investors design strategic landscapes.
Anti-Vegf Agents was the largest segment with a revenue share of 39.6% in 2025.
Horizon Databook has segmented the Asia Pacific ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy, gene & cell therapy covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific is expected to grow at the fastest rate of 10.0% over the forecast period. The increasing burden of ophthalmic disorders and rising consumer awareness are expected to drive market growth in Asia Pacific. Nearly two-thirds of the Asia Pacific population is vision impaired or blind.
The presence of a welldistributed network of clinical laboratories and hospitals in India is enabling an improved market penetration of ophthalmic drugs. In addition, rapid economic development and an increase in awareness programs in this region are anticipated to propel market growth.
Asia Pacific consists of a blend of developing and developed economies. Increasing healthcare expenditure in the region is anticipated to fuel market growth. The increasing geriatric population and rising awareness of dry eye syndrome are among the major factors driving the market in this region.
- Asia Pacific Ophthalmic Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Anti-Allergy
- Anti-VEGF agents
- Anti-glaucoma
- Gene & Cell Therapy
- Others
- Anti-inflammatory
- Asia Pacific Ophthalmic Drugs Market Disease Outlook (Revenue, USD Million , 2021-2033)
- Dry Eye
- Allergies
- Glaucoma
- Infection
- Retinal Disorders
- Uveitis
- Others
- Asia Pacific Ophthalmic Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical
- Systemic
- Local Ocular
- Asia Pacific Ophthalmic Drugs Market Dosage Type Outlook (Revenue, USD Million , 2021-2033)
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- Asia Pacific Ophthalmic Drugs Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- OTC drugs
- Prescription
- Asia Pacific Ophthalmic Drugs Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
- Branded Drugs
- Generic Drugs
Reasons to subscribe to Ophthalmic Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Ophthalmic Drugs Market Outlook databook
- Our clientele includes a mix of Ophthalmic Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Ophthalmic Drugs Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Ophthalmic Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Ophthalmic Drugs Market, 2021-2033 (US$M)
Asia Pacific ophthalmic drugs market statistics, by drug class, 2021-2033 (US$M)
